Clinical trials

# Metabolic advancing platform

## An integrated model to optimize metabolic trial delivery

The metabolic and obesity drug development pipeline is undergoing massive, rapid expansion. Success depends on more than a strong asset. As competition for resources, experienced sites and patients has intensified, expectations are rising across regulators, investors, payers, providers and patients. Long study durations, long-term compliance and tolerability, adherence risk and evolving study endpoints all add to increased operational complexity.

Under traditional models, sponsors typically manage multiple providers across trial delivery, sites, analytical services, technology systems, patient support, medical oversight, and evidence generation. This complicates and slows decision-making, leaving gaps between services that can impact execution.

### Our solution: A unified metabolic program strategy

The PPD™ clinical research business of Thermo Fisher Scientific has streamlined the intricacies of obesity and metabolic drug research with our metabolic advancing platform. While your team leads the science, our platform integrates specialized services to enable you to execute metabolic studies with greater speed, efficiency and confidence.

The platform brings together **trial management, analytical services, technology, site networks, scientific data surveillance, direct-to-patient support, and real-world evidence capabilities** in one integrated model. You gain a unified approach that reduces complexity, improves continuity and keeps teams focused on what matters most: startup acceleration, patient retention, data robustness, endpoint quality and long-term evidence generation.

### The advantages of our integrated metabolic services

- **Built-in flexibility.** Access the full platform or select services that fit your program.
- **Greater speed.** Accelerate startup, enrollment and study momentum.
- **Better retention.** Support patients through the factors that most influence adherence and study completion.
- **Stronger data.** Improve consistency across endpoints, study conduct and patient follow-through.
- **Broader evidence.** Inform clinical, regulatory and access decisions with longitudinal real-world insights on obesity treatment outcomes, safety, and adherence.
- **Reduced complexity.** Streamline vendor coordination and keep your team focused on the study.

### An integrated metabolic delivery platform

**Trials and programs management**
Dedicated metabolic teams delivering optimized study design and execution to drive faster enrollment, stronger retention, and reliable outcomes across all trial phases

**PPD™ CorEvitas™ Clinical Registries**
Real-world data and registry capabilities enabling longitudinal insights, cohort development, and evidence generation beyond the trial

**Medical communications solutions**
Patient-centric support programs, including navigation and lifestyle interventions, designed to improve engagement, adherence, and retention




**Drug development digital solutions**
AI-powered advanced digital solutions to provide you with clarity, confidence, and efficiency throughout the clinical trial journey

**Trialmed™ Global Site Network**
Access to high-performing investigational global clinical site network with proven metabolic experience, pre-qualified patient pools, and consistent enrollment delivery

**Data and biometrics**
Global medical and safety oversight ensuring scientific rigor, patient safety, and high-quality data across the study lifecycle in flexible models

# One platform. Combined services. Better study execution.

Our metabolic advancing platform integrates the services most critical to metabolic study performance so you can reduce complexity, improve continuity and generate stronger evidence across the development lifecycle.

## Trial management

A coordinated delivery model keeps strategy, timelines and execution aligned from startup through closeout. This collaborative framework minimizes complexity and achieves greater operational continuity with fewer handoffs and less vendor oversight.

## Study endpoints

Clario™, recently acquired by Thermo Fisher Scientific, provides integrated endpoint solutions that help sponsors and CROs evaluate treatment efficacy, safety, and patient impact. Combining specialized imaging, eCOA, cardiac safety, and digital health expertise with global operational scale and regulatory guidance, Clario generates high-quality evidence that demonstrates meaningful clinical outcomes, supports confident development and commercialization decisions, and helps therapies stand out in a competitive market.

## Technology

Drug development digital solutions by Thermo Fisher Scientific is implementing AI-enabled solutions to accelerate and optimize every phase of the clinical development journey by helping achieve faster study startups, smarter site selection, cleaner data, increased transparency, streamlined regulatory compliance, and greater confidence across the board.

## Global clinical site networks

Experienced, study-ready sites help sponsors compete for patients in a highly active market. The resources of Trialmed™ Global Site Network give you broad patient reach and a more predictable path to enrollment with over 7,300 prepooled active and ongoing patients for obesity and T2D, supported by 250+ sites worldwide.

## Medical & scientific data surveillance

Access to a proprietary scientific surveillance platform provides earlier visibility into emerging risks and study trends. This enables proactive measures while the trial is still underway, leading to confident Phase III readiness and interpretation

## Analytical services

Standard metabolic assays and specialized biomarker testing deliver scientific insights and comprehensive lab support. Our experience with more than 200 metabolic studies enables us to support emerging metabolic endpoints, GLP-1 safety, mechanism-based biomarkers and CVOTs.

## Patient navigator services offered as part of our medical communications solutions

Practical, patient-centered programs empower participants to stay engaged throughout the study. Patient navigator services reduce logistical and communication barriers, while lifestyle counseling manages expectations and long-term motivation.

## Real-world evidence and early evidence generation

Leveraging the PPD™ CorEvitas™ Obesity Registry, sponsors can optimize trial design, reduce development risk and generate real-world evidence to support differentiation, regulatory strategy and payer engagement. These longitudinal insights into safety, adherence and patient experience help demonstrate value across the product lifecycle.

## What sets our platform apart

- **Built for metabolic studies.** Designed around long study durations, tolerability challenges, retention risk and evidence collection beyond short-term weight loss.
- **Connected, not pieced together.** Services work together to reduce handoffs, align execution and improve continuity across the study lifecycle.
- **Designed for speed and predictability.** Experienced site access, centralized oversight and patient-centric participation models support faster, more reliable delivery.
- **Retention-focused by design.** Direct patient support, lifestyle counseling and site-facing readiness address real barriers to adherence in obesity and metabolic studies.
- **Complexity handled, efficiency unlocked.** Our seamless integrated model simplifies study management, substantially reducing vendor oversight.

## Let's strengthen your metabolic development strategy

Our metabolic advancing platform enables you to you boost operational execution and build stronger evidence across the metabolic development lifecycle. Whether you are interested in a fully integrated solution or selected capabilities, reach out to discuss how the platform can align to your obesity and metabolic programs.

Learn more at **ppd.com**